Skip to main content

Neuren Pharmaceuticals

Neuren Pharmaceuticals Ltd is an Australian biopharmaceutical company focused on the development of novel therapies for the treatment of serious neurological disorders characterized by neurodegeneration and neurodevelopmental delays, prominently featuring trofinetide (marketed as Daybue), a breakthrough treatment for Rett syndrome. The company conducts clinical research and pharmaceutical development for rare pediatric and neurological conditions, utilizing strategic commercial partnerships for global distribution. Its core business operations encompass biopharmaceutical research, clinical trial execution, drug formulation development, and commercial licensing management. Revenue is derived primarily from commercial product sales milestones, royalties on pharmaceutical sales, and licensing agreement fees. Neuren Pharmaceuticals holds a pioneering market position in rare neurological disease therapeutics. The company is headquartered in Melbourne, Victoria, Australia, and its shares trade on the Australian Securities Exchange.

7 of the funds FundTelligence covers report a position in Neuren Pharmaceuticals.

Legal name
Neuren Pharmaceuticals Ltd
Sector
Health Care
Country
Australia
Funds holding it
7

Funds holding Neuren Pharmaceuticals

Loading...